Monotherapy with minocycline or trimethoprim/sulfamethoxazole for treatment of Stenotrophomonas maltophilia infections

Journal of Antimicrobial Chemotherapy

Volumn 71, Issue 4, 2016, Pages 1071-1075

  Hand, Elizabeth ^a,b,c   Davis, Hannah ^a,b,c   Kim, Ted ^d   Duhon, Bryson ^a,b,c  

^a UNIVERSITY OF TEXAS AT AUSTIN   (United States)

^b UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^c University Health System   (United States)

^d Methodist Health Care   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CEFEPIME; CEFTAZIDIME; COTRIMOXAZOLE; LEVOFLOXACIN; MINOCYCLINE; MOXIFLOXACIN; TIMENTIN; ANTIINFECTIVE AGENT;

ACUTE KIDNEY FAILURE; ADULT; AGED; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM CULTURE; BACTERIUM ISOLATION; CHRONIC LUNG DISEASE; CLINICAL ARTICLE; COMPARATIVE EFFECTIVENESS; DRUG TREATMENT FAILURE; FEMALE; GRAM NEGATIVE INFECTION; HUMAN; MALE; MONOTHERAPY; MORTALITY; NONHUMAN; RETROSPECTIVE STUDY; STENOTROPHOMONAS MALTOPHILIA; STENOTROPHOMONAS MALTOPHILIA INFECTION; TREATMENT OUTCOME; ADOLESCENT; CHILD; COMORBIDITY; DRUG EFFECTS; GRAM-NEGATIVE BACTERIAL INFECTIONS; MICROBIOLOGY; MIDDLE AGED; MIXED INFECTION; TREATMENT FAILURE; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; CHILD; COINFECTION; COMORBIDITY; FEMALE; GRAM-NEGATIVE BACTERIAL INFECTIONS; HUMANS; MALE; MIDDLE AGED; MINOCYCLINE; RETROSPECTIVE STUDIES; STENOTROPHOMONAS MALTOPHILIA; TREATMENT FAILURE; TREATMENT OUTCOME; TRIMETHOPRIM, SULFAMETHOXAZOLE DRUG COMBINATION; YOUNG ADULT;

EID: 84962069288     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkv456     Document Type: Article

References (19)

1. Tsiodras S, Pittet D, Carmeli Y. Clinical implications of Stenotrophomonas maltophilia resistant to trimethoprim-sulfamethoxazole: a study of 69 patients at 2 university hospitals. Scand J Infect Dis 2000; 32: 651-6.
2. Falagas M, Valkimadi P, Huang Y et al. Therapeutic options for Stenotrophomonas maltophilia infections beyond co-trimoxazole: a systemic review. J Antimicrob Chemother 2008; 62: 889-94.
3. Pien C, Kuo H, Chang S et al. Risk factors for levofloxacin resistance in Stenotrophomonas maltophilia fromrespiratory tract in a regional hospital. J Microbiol Immunol Infect 2015; 48: 291-5.
4. Aisenberg G, Rolston K, Dickey B et al. Stenotrophomonas maltophilia pneumonia in cancer patients without traditional risk factors for infection, 1997-2004. Eur J Clin Microbiol Infect Dis 2007; 26: 13-20.
5. Guyot A, Turton J, Garner D. Outbreak of Stenotrophomonas maltophilia on an intensive care unit. J Hosp Infect 2013; 85: 303-7.
6. Garazi M, Singer C, Tai J et al. Bloodstream infections caused by Stenotrophomonas maltophilia: a seven-year review. J Hosp Infect 2012; 81: 114-8.
7. Wood G, Underwood E, Croce M et al. Treatment of recurrent Stenotrophomonas maltophilia ventilator-associated pneumonia with doxycycline and aerosolized colistin. Ann Pharmacother 2010; 44: 1665-8.
8. Saugel B, Eschermann K, Hoffmann R et al. Stenotrophomonas maltophilia in the respiratory tract of medial intensive care unit patients. Eur J Clin Microbiol Infect Dis 2012; 31: 1419-28.
9. LooneyW, Narita M, Muhlemann K et al. Stenotrophomonas maltophilia: an emerging opportunistic human pathogen. Lancet Infect Dis 2009; 9: 312-23.
10. Czosnowski Q, Wood C, Magnotti L et al. Clinical and microbiologic outcomes in trauma patients treated for Stenotrophomonas maltophilia ventilator associated pneumonia. Pharmacotherapy 2011; 31: 338-45.
11. Wang Y, Scipione M, Dubrovskaya Y et al. Monotherapy with fluoroquinolone or trimethoprim-sulfamethoxazole for treatment of Stenotrophomonas maltophilia infections. Antimicrob Agents Chemother 2014; 58: 176-82.
12. Cho SY, Kang C, Kim J et al. Can levofloxacin be a useful alternative to trimethoprim-sulfamethoxazole for treating Stenotrophomonas maltophilia bacteremia? Antimicrob Agents Chemother 2014; 58: 581-3.
13. Watanabe A, Anzai Y, Niitsuma K et al. Penetration of minocycline hydrochloride into lung tissue and sputum. Chemotherapy 2001; 47: 1-9.
14. Ritchie DJ, Garavaglia-Wilson A. A review of intravenous minocycline for treatment of multidrug-resistant Acinetobacter infections. Clin Infect Dis 2014; 59 (Suppl 6): S374-80.
15. Pogue JM, Neelakanta A, Mynatt RP et al. Carbapenem-resistance in gram-negative bacilli and intravenous minocycline: an antimicrobial stewardship approach at the Detroit Medical Center. Clin Infect Dis 2014; 59 Suppl 6: S388-93.
16. Venditti M, Monaco M, Micozzi A et al. In vitro activity of moxifloxacin against Stenotrophomonas maltophilia blood isolates from patients with hematologic malignancies. Clin Microbiol Infect 2001; 7: 37-9.
17. Samonis G, Karageorgopoulos DE, Maraki S et al. Stenotrophomonas maltophilia infections in a general hospital: patient characteristics, antimicrobial susceptibility, and treatment outcome. PLoS One 2012; 7: e37375.
18. Villarino ME, Stevens LE, Schable B et al. Risk factors for epidemic Xanthomonas maltophilia infection/colonization in intensive care unit patients. Infect Control Hosp Epidemiol 1992; 13: 201-6.
19. Vidigal PG, Dittmer S, SteinmannEet al. Adaptationof Stenotrophomonas maltophilia in cystic fibrosis: molecular diversity, mutation frequency and antibiotic resistance. Int J Med Microbiol 2014; 304: 613-9.